Ignite Creation Date:
2024-05-06 @ 1:11 PM
Last Modification Date:
2024-10-26 @ 1:10 PM
Study NCT ID:
NCT03952325
Status:
TERMINATED
Last Update Posted:
2021-07-30
First Post:
2019-05-14
Brief Title:
Tesetaxel Plus 3 Different PD-L1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC
Sponsor:
Odonate Therapeutics Inc
Organization:
Odonate Therapeutics Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Breast Cancer |
Keywords:
| Name | View |
|---|---|
| Central nervous system CNS metastases | View |
| Tesetaxel | View |
| PD-L1 inhibitor | View |
| Triple-negative breast cancer | View |
| Locally advanced or metastatic breast cancer | View |
| Taxane | View |
| Metastatic breast cancer | View |
| Breast cancer | View |
| Combination of tesetaxel and PD-L1 inhibitors | View |
| HER2 negative | View |
| Oral chemotherapy | View |